Pipeline › VK2735
VK2735
Not FDA-approved, and in phase 2 development, not authorised in the European Union. 4 active trials, the next due to complete 2027-07-01.
GIP/GLP-1 agonist, SC/oral, from Viking Therapeutics. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- GIP/GLP-1
- Route
- SC/oral
- Sponsor
- Viking Therapeutics
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 4 (4 in phase 3)
- Participants enrolled
- 6,720
- Trials with a reporting date
- 4
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-10-09 | New trial registered | Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 · Viking Therapeutics, Inc. | Not yet recruiting, n=560 | P3 |
| 2026-10-09 | New trial registered | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 · Viking Therapeutics, Inc. | Not yet recruiting, n=560 | P3 |
When these trials report
Next 4 of 4 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2027-07-01 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383 · Percent change in body weight from baseline to Week 78 in body weight | Viking Therapeutics, Inc. | P3 | 1,100 |
| 2027-07-01 | VK2735 for Weight Management Phase 3 NCT07104500 · Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment | Viking Therapeutics, Inc. | P3 | 4,500 |
| 2028-07 | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 · Percentage change in body weight for participants receiving VK2735 orally once daily | Viking Therapeutics, Inc. | P3 | 560 |
| 2028-10 | Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 · Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily | Viking Therapeutics, Inc. | P3 | 560 |
Indications under study
Weight Loss.
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2026-01-08 | Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, Ji S, Stubbe S, Hedges P, Lian B. | Obesity (Silver Spring) |
Every VK2735 trial on file
All 6 registered trials of VK2735, largest first. Each links to its own page and to the registry record.
| Trial | Status | Phase | Participants |
|---|---|---|---|
| VK2735 for Weight Management Phase 3 NCT07104500 · Viking Therapeutics, Inc. | Active, not recruiting | P3 | 4,500 |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383 · Viking Therapeutics, Inc. | Active, not recruiting | P3 | 1,100 |
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 · Viking Therapeutics, Inc. | Not yet recruiting | P3 | 560 |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 · Viking Therapeutics, Inc. | Not yet recruiting | P3 | 560 |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing) NCT06828055 · Viking Therapeutics, Inc. | Completed | P2 | 280 |
| VK2735 for Weight Management Phase 2 NCT06068946 · Viking Therapeutics, Inc. | Completed | P2 | 176 |